– Live webcast fireside chat on Wednesday, March 30th at 12:30 PM ET
GAINESVILLE, Fla. –
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that members of the Cyclo Therapeutics management team will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.
In addition to the Company’s corporate presentation available on demand for registered attendees, N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will participate in a live fireside chat moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group, on Wednesday, March 30, 2022, at 12:30 PM ET.
During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITs, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005564/en/
JTC Team, LLC